European CBD Hypertension study results are du

European CBD Hypertension study results are due to be published soon, and in an official medical journal no less.


Lexaria's European Study for lowering blood pressure with CBD and DehydraTECH is actually overdue. The results of this study were thought to be released as early as November, 2020. So investors could get this news at any time, and I expect this news to be a major catalyst.

https://ir.lexariabioscience.com/news-events/...pproval-to


Should the results prove positive (as they are expected to be) it will go hand in hand with the new European Patent LXRP just received for method of treatment claims for a broad range of disease conditions including cannabinoids to treat cardiac conditions such as hypertension (high blood pressure). This could be the first step toward wide-ranging adoption of DehydraTech for a broad range of big pharma drugs.


https://ir.lexariabioscience.com/news-events/...patent-for


In my opinion, this development could be huge for Lexaria. The company is shaping up for some big strides in the very near future because the hypertension market alone is worth over 45 billion dollars. Chris Bunka (CEO of Lexaria) has stated repeatedly he intends to up-list to a major exchange, and the adoption of DehydraTech by big pharma may just be that ticket.


Kgem







Read More: https://investorshangout.com/post/view?id=598...z6fx3oLky1